The shares of Pfizer Inc. (NYSE:PFE) has been pegged with a rating of Neutral by Citigroup in its latest research note that was published on February 20th, 2019. The research company has also assigned a $41 price target. Citigroup wasn’t the only research firm that published a report of Pfizer Inc., with other equities research analysts also giving their opinion on the stock. Credit Suisse advised investors in its research note published on January 31st, 2019, to Outperform the PFE stock. The stock had earned Buy rating from Argus when it published its report on January 31st, 2019. The stock was given Neutral rating by UBS in its report released on January 23rd, 2019. JP Morgan was of a view that PFE is Neutral in its latest report on December 11th, 2018. BMO Capital Markets thinks that PFE is worth Market Perform rating. This was contained in the firm’s report on November 1st, 2018.
Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 6 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $45.00. The price of the stock the last time has raised by 18.88% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 61.03.
The shares of the company added by 0.77% during the trading session on Wednesday, reaching a low of $41.55 while ending the day at $41.99. During the trading session, a total of 23.96 million shares were traded which represents a -2.11% decline from the average session volume which is 23.46M shares. PFE had ended its last session trading at 41.67. Pfizer Inc. currently has a market cap of $234.42B, while its P/E ratio stands at 23.25, while its P/E earnings growth sits at 4.35, with a beta of 0.69. Pfizer Inc. debt-to-equity ratio currently stands at 0.77, while its quick ratio hovers at 1.30. PFE 52-week low price stands at $35.32 while its 52-week high price is $46.47.
The company in its last quarterly report recorded $0.85 earnings per share which is above the $0.75 predicted by most analysts. The Pfizer Inc. generated $13,118.00 million in revenue during the last quarter, which is slightly higher than the $12,990.60 million predicted by analysts. In the second quarter last year, the firm recorded $0.64 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 24.71%. Pfizer Inc. has the potential to record 1.81 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Telsey Advisory Group published a research note on May 22nd, 2019 where it informed investors and clients that Nordstrom, Inc. (NYSE:JWN) is now rated as Market Perform. Their price target on the stock stands at $37. Credit Suisse also rated JWN as Upgrade on January 31st, 2019, with its price target of $2 suggesting that JWN could surge by 28.15% from its current share price. Even though the stock has been trading at $37.85/share, analysts expect it to surge higher by -9.25% to reach $47.81/share. It started the day trading at $35.21 and traded between $33.75 and $34.35 throughout the trading session.
A look at its technical shows that JWN’s 50-day SMA is 42.00 while its 200-day SMA stands at 51.06. The stock has a high of $67.75 for the year while the low is $36.37. The company’s P/E ratio currently sits at 10.39, while the P/B ratio is 6.49. At the moment, only of Nordstrom, Inc. shares were sold short. The company’s average trading volume currently stands at 3.12M shares, which means that the short-interest ratio is just 6.98 days. Over the past seven days, the company moved, with its shift of -8.23%. Looking further, the stock has dropped -22.79% over the past 90 days while it lost -32.55% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more JWN shares, increasing its portfolio by +5.55% during the last quarter. This move now sees The Vanguard Group Inc purchasing 749,715 shares in the last quarter, thus it now holds 14,252,058 shares of JWN, with a total valuation of $584,619,419. BlackRock Fund Advisors meanwhile sold more JWN shares in the recently filed quarter, changing its stake to $283,540,864 worth of shares. SSgA Funds Management Inc followed the path by increasing its JWN portfolio by +5.22% in the quarter. This means that SSgA Funds Management Inc bought 330,060 shares in the last quarter and now controls 6,652,048 shares of the JWN stock, with the valuation hitting $272,867,009.
Similarly, Mellon Investments Corp increased its Nordstrom, Inc. shares by +1.90% during the recently filed quarter. After buying 70,132 shares in the last quarter, the firm now controls 3,759,832 shares of Nordstrom, Inc. which are valued at $154,228,309. In the same vein, Northern Trust Investments Inc decreased its Nordstrom, Inc. shares by during the most recent reported quarter. The firm sold -55,976 shares during the quarter which decreased its stakes to 1,653,801 shares and is now valued at $67,838,917. Following these latest developments, around 10.40% of Nordstrom, Inc. stocks are owned by institutional investors and hedge funds.